Concepedia

Author

Martin Wermke

University Hospital Carl Gustav CarusORCID

Also Known As

D Haase, M Wermke, M. Wermke, Martin Wermke, Wermke M

290

Publications

8K

Citations

42

H-Index

93

Concepts

All Affiliations

University Hospital Carl Gustav CarusTechnische Universität DresdenHeidelberg UniversityUniversitätsklinikum WürzburgNational Center for Tumor Diseases
MW

About

Martin Wermke is an author at University Hospital Carl Gustav Carus specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

34

1.7K

2

Engineering

3

3

198

3

Health Sciences

2

2

424

4

Language Studies

1

1

22

5

Public Health

1

1

23

Martin Wermke

×

96

Publications

7.1K

Citations

40

H-Index

YearCitations

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr,

Blood

2002

1.7K

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke,

Leukemia

2011

391

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig,

Blood Cancer Journal

2014

344

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster,

Blood

2020

307

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila,

The Lancet Oncology

2019

271

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Jason Chesney, Karl D. Lewis, Harriet M. Kluger,

Journal for ImmunoTherapy of Cancer

2022

268

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

Christoph Röllig, Christian Thiede, Martin Gramatzki,

Blood

2010

175

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma, Martin Wermke, Virginia M. Klimek,

Leukemia

2021

169

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan,

Journal for ImmunoTherapy of Cancer

2018

164

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger,

Blood

2021

160

Page 1